Search results for "amp"

showing 10 items of 10184 documents

NO Hemodynamic Speed Limit for Hippocampal Neurogenesis

2019

Newborn dentate granule cells (DGCs) are continuously generated in the adult brain. The mechanism underlying how the adult brain governs hippocampal neurogenesis remains poorly understood. In this study, we investigated how coupling of pre-existing neurons to the cerebrovascular system regulates hippocampal neurogenesis. Using a new in vivo imaging method in freely moving mice, we found that hippocampus-engaged behaviors, such as exploration in a novel environment, rapidly increased microvascular blood flow velocity in the dentate gyrus. Importantly, blocking this exploration-elevated blood flow dampened experience-induced hippocampal neurogenesis. By imaging the neurovascular niche in comb…

0301 basic medicineNeurogenesisGeneral NeuroscienceNeurogenesisHemodynamicsHemodynamicsHippocampal formationBiologyHippocampusArticleCoupling (electronics)03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structurenervous systemNeuroblastVascular flowDentate GyrusmedicineNeurovascular CouplingNeuronNeuroscience030217 neurology & neurosurgeryNeuron
researchProduct

Auxiliary α2δ1 and α2δ3 Subunits of Calcium Channels Drive Excitatory and Inhibitory Neuronal Network Development

2020

VGCCs are multisubunit complexes that play a crucial role in neuronal signaling. Auxiliary α2δ subunits of VGCCs modulate trafficking and biophysical properties of the pore-forming α1 subunit and trigger excitatory synaptogenesis. Alterations in the expression level of α2δ subunits were implicated in several syndromes and diseases, including chronic neuropathic pain, autism, and epilepsy. However, the contribution of distinct α2δ subunits to excitatory/inhibitory imbalance and aberrant network connectivity characteristic for these pathologic conditions remains unclear. Here, we show that α2δ1 overexpression enhances spontaneous neuronal network activity in developing and mature cultures of …

0301 basic medicineNeurogenesisSynaptogenesisNeurotransmissionInhibitory postsynaptic potentialHippocampusSynaptic Transmission03 medical and health sciencesGlutamatergicMice0302 clinical medicineVGCCsexcitation to inhibition balanceBiological neural networkPremovement neuronal activityAnimalsHumansCalcium SignalingResearch ArticlesNeuronssynaptogenesisChemistryGeneral NeuroscienceGlutamate receptornetwork connectivityRats030104 developmental biologyHEK293 CellsExcitatory postsynaptic potentialalpha2delta subunitsCalcium ChannelsNerve NetNeuroscience030217 neurology & neurosurgeryCellular/MolecularThe Journal of Neuroscience
researchProduct

Asymmetry Between Pre- and Postsynaptic Transient Nanodomains Shapes Neuronal Communication.

2020

Synaptic transmission and plasticity are shaped by the dynamic reorganization of signaling molecules within pre- and postsynaptic compartments. The nanoscale organization of key effector molecules has been revealed by single-particle trajectory (SPT) methods. Interestingly, this nanoscale organization is highly heterogeneous. For example, presynaptic voltage-gated calcium channels (VGCCs) and postsynaptic ligand-gated ion channels such as AMPA receptors (AMPARs) are organized into so-called nanodomains where individual molecules are only transiently trapped. These pre- and postsynaptic nanodomains are characterized by a high density of molecules but differ in their molecular organization an…

0301 basic medicineNeuronsCell signalingNeuronal PlasticityVoltage-dependent calcium channelEffectorChemistryGeneral NeuroscienceAMPA receptorNeurotransmissionSynaptic Transmission03 medical and health sciencesMolecular dynamics030104 developmental biology0302 clinical medicinePostsynaptic potentialSynapsesBiophysicsHumansReceptors AMPA030217 neurology & neurosurgeryIon channelTrends in neurosciences
researchProduct

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final…

2016

Summary Background FIRE-3 compared first-line 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab with FOLFIRI plus bevacizumab in patients with KRAS exon 2 wild-type metastatic colorectal cancer. The same study also reported an exploratory analysis of a subgroup of patients with tumours that were wild-type at other RAS genes ( KRAS and NRAS exons 2–4). We report here efficacy results for the FIRE-3 final RAS ( KRAS/NRAS , exons 2–4) wild-type subgroup. Moreover, new metrics of tumour dynamics were explored during a centralised radiological review to investigate how FOLFIRI plus cetuximab conferred overall survival benefit in the absence of differences in investigator-assess…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyBevacizumabColorectal cancerPopulationLeucovorinCetuximabmedicine.disease_cause03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansNeoplasm MetastasiseducationResponse Evaluation Criteria in Solid TumorsAgededucation.field_of_studyCetuximabbusiness.industryMiddle Agedmedicine.diseaseIrinotecanBevacizumab030104 developmental biologyGenes rasOncologyResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisFOLFIRICamptothecinFemaleKRASFluorouracilbusinessColorectal NeoplasmsTomography X-Ray Computedmedicine.drugThe Lancet. Oncology
researchProduct

Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.

2018

Abstract Background Neuroblastoma is characterized by substantial clinical heterogeneity. Despite intensive treatment, the survival rates of high-risk neuroblastoma patients are still disappointingly low. Somatic chromosomal copy number aberrations have been shown to be associated with patient outcome, particularly in low- and intermediate-risk neuroblastoma patients. To improve outcome prediction in high-risk neuroblastoma, we aimed to design a prognostic classification method based on copy number aberrations. Methods In an international collaboration, normalized high-resolution DNA copy number data (arrayCGH and SNP arrays) from 556 high-risk neuroblastomas obtained at diagnosis were coll…

0301 basic medicineOncologyCancer ResearchSomatic cellNeuroblastoma0302 clinical medicineGene duplicationMedicine and Health SciencesHigh risk neuroblastomaN-Myc Proto-Oncogene ProteinABNORMALITIESIntensive treatmentGenomicsArticlesPrognosis3. Good healthOncologyChild Preschool030220 oncology & carcinogenesisChromosomes Human Pair 6Chromosome DeletionINTEGRATIONmedicine.medical_specialtyDNA Copy Number VariationsCLASSIFICATION03 medical and health sciencesAGEInternal medicineNeuroblastomaSTRATIFICATIONClinical heterogeneityBiomarkers TumormedicineHumansGenetic Predisposition to DiseaseCopy number aberrationneoplasmsGenetic Association StudiesNeoplasm StagingACCUMULATIONbusiness.industryOUTCOME PREDICTIONGene AmplificationInfantBiology and Life SciencesDNAmedicine.diseaseDELINEATION030104 developmental biologyCOPY NUMBEROutcome predictionbusiness
researchProduct

Prospective validation of a blood-based 9-miRNA profile for early detection of breast cancer in a cohort of women examined by clinical mammography

2016

Mammography is the predominant screening method for early detection of breast cancer, but has limitations and could be rendered more accurate by combination with a blood-based biomarker profile. Circulating microRNAs (miRNAs) are increasingly recognized as strong biomarkers, and we previously developed a 9-miRNA profile using serum and LNA-based qPCR that effectively stratified patients with early stage breast cancer vs. healthy women. To further develop the test into routine clinical practice, we collected serum of women examined by clinical mammography (N = 197) according to standard operational procedures (SOPs) of the Danish Cancer Biobank. The performance of the circulating 9-miRNA pro…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyEarly detectionBreast NeoplasmsCancer BiobankDisease03 medical and health sciences0302 clinical medicineBreast cancerInternal medicinemicroRNABiomarkers TumorGeneticsmedicineHumansMammographyBreastProspective StudiesStage (cooking)Research ArticlesAgedGynecologymedicine.diagnostic_testbusiness.industryGene Expression ProfilingGeneral MedicineMiddle AgedPrognosismedicine.diseaseMicroRNAs030104 developmental biologyOncology030220 oncology & carcinogenesisCohortMolecular MedicineBiomarker (medicine)FemaleSample collectionbusinessMammography
researchProduct

Trifluridine/tipiracil : an emerging strategy for the management of gastrointestinal cancers

2018

Fluoropyrimidines are currently the backbone of treatment for gastrointestinal (GI) cancers but development of resistance to these agents remains a major problem. Trifluridine/tipiracil is an oral chemotherapeutic agent recently approved for third-line treatment of chemorefractory metastatic colorectal cancer. This article reviews the clinical value of trifluridine/tipiracil as a monotherapy, including recent trials in GI cancers, and the potential benefit of combining it with other agents in patients with GI cancers, including the preclinical rationale for combination therapy and recently completed and ongoing clinical trials. Data gathered so far suggest that trifluridine/tipiracil has t…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyIndolesPyrrolidinesOrganoplatinum CompoundsCombination therapyColorectal cancerTrifluridineDocetaxelIrinotecanTrifluridine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansGastrointestinal cancerContinuum of careUracilGastrointestinal NeoplasmsTipiracilClinical Trials as Topicbusiness.industryGeneral Medicinemedicine.diseaseBevacizumabOxaliplatinClinical trialDrug Combinations030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisColonic NeoplasmsQuality of LifeClinical valueCamptothecinTaxoidsFluorouracilImmunotherapyHuman medicinebusinessThyminemedicine.drugFuture oncology
researchProduct

Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry—Comparison of Three Different GPA Prognostic Scores

2021

Several scores have been developed in order to estimate the prognosis of patients with brain metastases (BM) by objective criteria. The aim of this analysis was to validate all three published graded-prognostic-assessment (GPA)-scores in a subcohort of 882 breast cancer (BC) patients with BM in the Brain Metastases in the German Breast Cancer (BMBC) registry. The median age at diagnosis of BM was 57 years. All in all, 22.3% of patients (n = 197) had triple-negative, 33.4% (n = 295) luminal A like, 25.1% (n = 221) luminal B/HER2-enriched like and 19.2% (n = 169) HER2 positive like BC. Age ≥60 years, evidence of extracranial metastases (ECM), higher number of BM, triple-negative subtype and l…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyNeoplasm metastasisAge at diagnosisPrognoseDiagnostic accuracylcsh:RC254-282ArticleMetastasis03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerInternal medicinebrain metastasesOverall survivalBrustkrebsMedicineddc:610HirnmetastaseUnivariate analysisbusiness.industryBrainLuminal aLuminal blcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePrognosis030104 developmental biologyOncology030220 oncology & carcinogenesisBreast; CancerPrognostic groupBreast neoplasmsbusinessDDC 610 / Medicine & healthprognostic scoresCancers
researchProduct

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma …

2019

Abstract Background Bevacizumab, a VEGF‐A inhibitor, in combination with chemotherapy, has proven to increase progression‐free survival (PFS) and overall survival in multiple lines of therapy of metastatic colorectal cancer (mCRC). The angiogenic factor angiopoetin‐2 (Ang‐2) is associated with poor prognosis in many cancers, including mCRC. Preclinical models demonstrate improved activity when inhibiting both VEGF‐A and Ang‐2, suggesting that the dual VEGF‐A and Ang‐2 blocker vanucizumab (RO5520985 or RG‐7221) may improve clinical outcomes. This phase II trial evaluated the efficacy of vanucizumab plus modified (m)FOLFOX‐6 (folinic acid (leucovorin), fluorouracil (5‐FU) and oxaliplatin) ver…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyVEGF‐AVanucizumab20BevacizumabAngiopoetin-26Organoplatinum CompoundsColorectal cancerLeucovorinPhases of clinical researchFirst‐line metastatic colorectal cancerAntibodies Monoclonal HumanizedVEGF-ADisease-Free SurvivalMetastasis03 medical and health sciencesFolinic acid0302 clinical medicineMetàstasiCàncer colorectalInternal medicineGastrointestinal CancerAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansNeoplasm MetastasisAngiopoetin‐2business.industryHazard ratiomedicine.diseaseColorectal cancerOxaliplatinBevacizumab030104 developmental biologyOncologyFluorouracil030220 oncology & carcinogenesisCamptothecinFluorouracilbusinessColorectal NeoplasmsFirst-line metastatic colorectal cancermedicine.drug
researchProduct

Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients

2020

MET alterations may provide a potential biomarker to evaluate patients who will benefit from treatment with MET inhibitors. Therefore, the purpose of the present study is to investigate the utility of a liquid biopsy-based strategy to assess MET alterations in cancer patients. We analyzed MET amplification in circulating free DNA (cfDNA) from 174 patients with cancer and 49 healthy controls and demonstrated the accuracy of the analysis to detect its alteration in patients. Importantly, a significant correlation between cfDNA concentration and MET copy number (CN) in cancer patients (r = 0.57, p &lt

0301 basic medicineOncologyMale<i>MET</i> copy numbermedicine.medical_treatmentproteínas protooncogénicas c-metdosificación génicahumanosresistencia a medicamentosDrug ResistanceGene Dosagecirculating free DNA (cfDNA)<i>MET</i> amplificationTargeted therapyTargeted therapy0302 clinical medicineCirculating tumor cellestudios prospectivosNeoplasmsantineoplásicosProspective Studieslcsh:QH301-705.5Circulating tumor cells (CTCs)neoplasiasGeneral MedicineProto-Oncogene Proteins c-mettargeted therapyNeoplastic Cells CirculatingErbB ReceptorsCell-free fetal DNA030220 oncology & carcinogenesisinhibidores de proteína cinasasBiomarker (medicine)FemaleMET protein expressionCell-Free Nucleic AcidsMET amplificationmedicine.medical_specialtycirculating tumor cells (CTCs)estudios de casos y controlesMet amplificationCirculating free DNA (cfDNA)Antineoplastic AgentsArticle03 medical and health sciencesInternal medicinemedicineBiomarkers TumorHumansLiquid biopsyProtein Kinase InhibitorsRetrospective Studiesbusiness.industryHead and neck cancerestudios retrospectivosLiquid BiopsyCancermedicine.disease030104 developmental biologylcsh:Biology (General)Drug Resistance NeoplasmCase-Control StudiesMET copy numberbusinessCells
researchProduct